Clear Guidelines for IND/CTA

Overview


Clear-Guidelines-for-IND-CTA.png

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful assessment of efficacy and toxicity prior to entering human trials. This document is intended to provide clear guidelines to help you plan your nonclinical assessment.

Altasciences' IND expertise and integrated processes can help you advance your drug development, faster. For a process overview and handy checklist, read more here:

This content is provided by Altasciences, and any views and opinions expressed do not necessarily reflect those of Outsourcing-Pharma.com

Download Now


Related Resources

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences

White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs), including: a review of the relevant guidance HPAPI classification systems safety processes...

CNS Drug Development―One Partner From Discovery to Market

CNS Drug Development―One Partner From Discovery to Market

Content provided by Altasciences

White Paper

As a leading partner in central nervous system (CNS) drug development, Altasciences’ in-house preclinical, clinical, bioanalytical, and manufacturing teams have decades of experience formulating, testing, and manufacturing pharmaceutical products that...

Supplier Info Centre

Altasciences.jpg

For more product information visit Altasciences.